692058-31-4

Basic information

• Product Name: (3aR,6aS)-rel-tetrahydro-4H-1,3-Dioxolo[4,5-c]pyrrole (Relative struc)
• Synonyms: (3aR,6aS)-rel-tetrahydro-4H-1,3-Dioxolo[4,5-c]pyrrole (Relative struc)
• CAS NO: 692058-31-4
• Molecular Formula: C5H9NO2
• Molecular Weight: 115.13
• Mol File: 692058-31-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3aR,6aS)-rel-tetrahydro-4H-1,3-Dioxolo[4,5-c]pyrrole (Relative struc)(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,6aS)-rel-tetrahydro-4H-1,3-Dioxolo[4,5-c]pyrrole (Relative struc)(692058-31-4)
• EPA Substance Registry System: (3aR,6aS)-rel-tetrahydro-4H-1,3-Dioxolo[4,5-c]pyrrole (Relative struc)(692058-31-4)

Safety Data

• Hazardous Substances Data: 692058-31-4(Hazardous Substances Data)

Upstream product

• 1152110-36-5 benzyl (3aR,6aS)-tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate 
• 612501-79-8 (3RS,4SR)-3,4-methylenedioxypyrrolidine hydrochloride 
• 692058-52-9 (3aR,6aS)-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole hydrochloride 

Relevant articles and documents

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.